Natco Pharma, the Hyderabad based generic drug maker, is all set to take on the global pharma major Teva in a case related to generic Copaxone indicated for multiple sclerosis. Natco with Mylan has filed an abbreviated new drug application with the US Food and Drug Administration (FDA) for marketing Copaxone clone in the
Meanwhile, Teva has filed a citizen's petition (CP) alleging that generic drug makers can't show their drug is a precise copy of Copaxone -- a fact that should preclude market approval. A CP normally delays the launch plans of generic companies as the FDA tries to work on the objections raised by the company, which is already marketing its product. In fact, Teva had filed one such CP in 2008 but failed in convincing the authorities.
The generic by Natco would offer a significant upside once its ANDA is approved by the regulator.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: